Younger women (<55 years of age) with early-stage ER + breast cancer who were given no adjuvant systemic therapy had a significantly lower risk of relapse when their tumor had high TRIM29 expression, suggesting that loss of TRIM29 expression in normal breast luminal cells can contribute to malignant transformation and lead to progression of ER + breast cancer in premenopausal women [19]. This evidence concerns the gene TRIM29 and neoplasm.